MAP: Microbiome Diagnostics — The Patient-Pay Problem

MAP · ASX:A pre-profitable diagnostics company targeting gut health disorders with proprietary testing — we examine whether first-mover database advantages justify current valuations in a patient-pay market.
1 / 6

MAP: Microbiome Diagnostics — The Patient-Pay Problem

💡

In a Nutshell

Executive Summary